PF-04191834

PF-04191834 (also known as PF-4191834) is an orally available, synthetic small molecule that acts as a selective, non-redox inhibitor of the enzyme 5-lipoxygenase (ALOX5). This enzyme catalyzes the conversion of arachidonic acid to leukotrienes, which are potent mediators of inflammation. By inhibiting ALOX5, PF-04191834 reduces the production of proinflammatory lipid mediators and has potential anti-inflammatory and analgesic effects. The drug was initially developed by Pfizer for indications such as asthma and osteoarthritis; however, clinical development has been discontinued[1][2][3][6].

Other names

1029317-21-2UNII-YX55DXP4T1UNII-YX-55DXP4T1UNII-YX 55DXP4T1YX55DXP4T1YX-55DXP4T1YX 55DXP4T14-(3-(4-(1-methyl-1H-pyrazol-5-yl)phenylthio)phenyl)-tetrahydro-2H-pyran-4-carboxamide4-[3-[4-(2-methylpyrazol–3–yl)phenyl]sulfanylphenyl]oxane–4–carboxamide